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Abstract
Background: MMP-13 and IGFBP-5 are important factors involved in osteoarthritis (OA). We
investigated whether two highly predicted microRNAs (miRNAs), miR-140 and miR-27a, regulate
these two genes in human OA chondrocytes.
Methods: Gene expression was determined by real-time PCR. The effect of each miRNA on
IGFBP-5 and MMP-13 expression/production was evaluated by transiently transfecting their
precursors (pre-miRNAs) and inhibitors (anti-miRNAs) into human OA chondrocytes. Modulation
of IGFBP-5, miR-140 and miR-27a expression was determined upon treatment of OA chondrocytes
with cytokines and growth factors.
Results: IGFBP-5 was expressed in human chondrocytes with its level significantly lower (p < 0.04)
in OA. Five computational algorithms identified miR-140 and miR-27a as possible regulators of
MMP-13 and IGFBP-5 expression. Data showed that both miRNAs were expressed in
chondrocytes. There was a significant reduction (77%, p < 0.01) in miR-140 expression in OA
compared to the normal chondrocytes, whereas miR-27a expression was only slightly decreased
(23%). Transfection with pre-miR-140 significantly decreased (p = 0.0002) and with anti-miR-140
significantly increased (p = 0.05) IGFBP-5 expression at 24 hours, while pre-miR-27a did not affect
either MMP-13 or IGFBP-5. Treatment with anti-miR-27a, but not with anti-miR-140, significantly
increased the expression of both MMP-13 (p < 0.05) and IGFBP-5 (p < 0.01) after 72 hours of
incubation. MMP-13 and IGFBP-5 protein production followed the same pattern as their expression
profile. These data suggest that IGFBP-5 is a direct target of miR-140, whereas miR-27a down-
regulates, likely indirectly, both MMP-13 and IGFBP-5.
Conclusion: This study is the first to show the regulation of these miRNAs in human OA
chondrocytes. Their effect on two genes involved in OA pathophysiology adds another level of
complexity to gene regulation, which could open up novel avenues in OA therapeutic strategies.
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Background
Many factors contribute to the overall degradation of car-
tilage observed in osteoarthritis (OA), either directly or
indirectly by modulating anabolic factors. Examples of
such molecules are the matrix metalloprotease (MMP)-13
and the insulin-like growth factor binding protein
(IGFBP)-5. MMP-13 is a well known key player in carti-
lage biology and OA pathology because of its capacity to
degrade, in addition to collagens, a wide range of matrix
components [1-6]. Although a large number of factors
including pro-inflammatory cytokines, growth factors,
and fibronectin fragments have been reported to regulate
MMP-13 expression [5,7,8], further knowledge about its
regulation is needed in order to identify factors that could
specifically inhibit this MMP while sparing others and, as
such, avoid the unwanted side effects observed with broad
spectrum MMP inhibitors [9,10]. IGFBPs are proteins
known to modulate the availability/activity of the ana-
bolic factor IGF-1. Evidence has shown that in the joint,
IGFBP-5 plays an important storage role for IGF-1 [11].
Furthermore, results from a study using an OA dog model
demonstrated that increasing IGFBP-5 concentration led
to an increased level of IGF-1 and was associated with a
reduction in cartilage destruction [12]. Despite its regula-
tory role in cartilage, the regulation of human IGFBP-5
itself has not yet been investigated in this tissue or in
chondrocytes.
Although MMP-13 promoter regulation has been the sub-
ject of many publications [13-16], there is no report on
the role of 3'-untranslated regions (3'-UTRs) on either its
regulation or that of IGFBP-5. Since microRNAs (miR-
NAs) act on this region and are important regulators of
gene expression, we investigated whether MMP-13 and
IGFBP-5 are the targets of specific miRNAs.
miRNAs are small non-coding RNAs (20-25 nucleotides)
naturally produced by the cells. They are derived from pri-
mary miRNA transcripts (70-100 nucleotides) that are
processed in the nucleus to precursor miRNAs (pre-miR-
NAs) by the ribonuclease Drosha [17]. The pre-miRNAs
are then transported into the cytoplasm where they are
further processed into miRNAs by the ribonuclease Dicer
[18]. The miRNAs play a role in gene silencing by regulat-
ing the stability or translational efficiency of target mes-
senger RNA (mRNA). Depending on the degree of base
pairing between the miRNA and the target mRNAs, the
miRNAs either repress translation (imperfect pairing) or
cleave the mRNAs (perfect pairing) [19]. Pairing generally
occurs in the 3'UTR of the mRNAs. Another mechanism of
miRNA-mediated mRNA degradation may involve AU-
rich elements (AREs), which are located in the 3'-UTR of
unstable mRNAs [20].
Several hundred miRNAs have been identified so far and
initial studies have linked specific miRNAs to different tis-
sues, developmental processes, and pathologies such as
cancer [21-23]. Although algorithms are used to predict
potential mRNA targets, only a few miRNAs have been
validated and assigned to specific mRNAs.
The cellular outcomes of miRNA-mediated gene regula-
tion are complex, as some miRNAs decrease while others
increase cell growth, and still others increase the level of
apoptosis [22]. However, because of their role, miRNAs
may represent another avenue for therapeutic interven-
tion in arthritic diseases.
The importance of miRNAs in joint pathologies and in
inflammatory events has been addressed only recently.
Stanczyk et al [24] reported that the expression of miR-
155 and miR-146a was increased in synovial fibroblasts
from rheumatoid arthritis (RA) patients as compared to
OA. The miR-146 was also found to be up-regulated in
peripheral blood mononuclear cells [25] and in synovial
tissues [26] from RA patients. Moreover, the expression of
miR-146 and miR-155 was also shown to be up-regulated
by bacterial endotoxins and the pro-inflammatory
cytokines interleukin-1β (IL-1β) and tumor necrosis fac-
tor-α (TNF-α) [27]. In a recent study [28], miR-146a was
reported to be expressed mostly in OA cartilage showing
mild scores and its expression was stimulated in normal
chondrocytes by IL-1β. These findings thus suggest that
some miRNAs could be of importance in the inflamma-
tory events of arthritis.
There have been few reports on the role of miRNAs in car-
tilage biology. Tuddenham et al [29] reported the pres-
ence of miR-140 in cartilaginous tissues of the developing
mouse and showed that this miRNA targeted the mouse
histone deacetylase 4 mRNA. Kobayashi et al [30] showed
that Dicer, an enzyme involved in the miRNA pathway,
was essential for chondrocyte function in mice; the
growth plates from Dicer-null mice demonstrated a pro-
gressive reduction in the proliferating pool of chondro-
cytes, leading to severe skeletal growth defects and
premature death of the mice. The miR-199* was also
recently shown to control chondrogenesis in mice, via
direct targeting to Smad1 [31]. In humans, there is to our
knowledge only one study in which the miRNAs have
been profiled comparing normal and OA cartilage [32]. In
this study it was found that 16 miRNAs were differentially
expressed when OA was compared to normal cartilage.
Moreover, comparison with clinical data revealed that
some miRNAs (miR-22 and miR-33) and proteins, perox-
isome proliferator-activated receptor-α (PPARα), bone
morphogenic protein-7 (BMP-7) and IL-1β, highly corre-
late with body mass index. Moreover, as mentioned
above, miR-146a has also been found expressed in a sub-
set of OA cartilage [28].BMC Musculoskeletal Disorders 2009, 10:148 http://www.biomedcentral.com/1471-2474/10/148
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We thus investigated whether MMP-13 and IGFBP-5 are
regulated by miRNAs in human OA chondrocytes. We
identified the miRNAs miR-140 and miR-27a as regula-
tors of these two genes and studied their expression and
regulation in normal and OA human chondrocytes. This
study provides a more comprehensive understanding of
the overall regulation of MMP-13 and IGFBP-5.
Methods
Specimen selection
Human cartilage was obtained from femoral condyles and
tibial plateaus. Normal (control) cartilage was obtained
from individuals within 12 hours of death (mean age ±
SEM: 57 ± 8 years). These individuals had no history of
joint disease and died of causes unrelated to arthritic dis-
eases. The tissues were examined macroscopically and
microscopically to ensure that only normal tissue was
used. Human OA cartilage was obtained from patients
undergoing total knee arthroplasty (72 ± 2 years). All
patients had been evaluated by a certified rheumatologist
and diagnosed as having OA according to the American
College of Rheumatology criteria [33]. These specimens
represented moderate to severe OA [34]. At the time of
surgery, the patients had symptomatic disease requiring
medical treatment. None had received intra-articular ster-
oid injections within three months prior to surgery. The
Institutional Ethics Committee Board of the Notre-Dame
Hospital approved the use of the human articular tissues
and patients signed informed consent.
Cell culture
Chondrocytes were released from cartilage by sequential
enzymatic digestion at 37°C, as previously described
[5,8]. The cells were seeded at high density (105/cm2) and
cultured in Dulbecco's modified Eagle's medium (DMEM;
Gibco BRL, Burlington, ON, Canada) supplemented with
10% heat-inactivated fetal calf serum (FCS; Gibco BRL)
and an antibiotic mixture (100 units/ml penicillin base
and 100 μg/ml streptomycin base; Gibco BRL) at 37°C in
a humidified atmosphere. Primary chondrocytes were
used when comparing expression levels in normal and OA
chondrocytes; first-passage cultured chondrocytes were
used in the other experiments.
The effects of cytokines and growth factors on IGFBP-5
and miRNA expression levels were assessed by pre-incu-
bating confluent chondrocytes in DMEM/0.5% FCS for 20
hours containing the following factors: IL-1β (100 pg/
ml), TNF-α (5 ng/ml), interferon-γ (IFN-γ, 10 U/ml), IL-4
(10 ng/ml), IL-10 (10 ng/ml), transforming growth factor-
β (TGF-β, 10 ng/ml), BMP-2 (10 ng/ml), and epidermal
growth factor (EGF, 10 ng/ml). The expression levels of
IGFBP-5, miR-140, and miR-27a were quantified by real-
time polymerase chain reaction (PCR).
Total RNA extraction and real-time PCR
Total RNA was extracted, quantified and treated with
DNase as described previously [35]. Real time PCR was
performed in the Rotor-Gene RG-3000A (Corbett
Research, Mortlake, Australia) with the SYBR Green PCR
Master Mix (Qiagen, Valencia, CA, USA). The PCR param-
eters were as described [35]. The data were given as a
threshold cycle (Ct). Fold changes in gene expression were
calculated as 2-Δ(ΔCt). The primer efficiencies for the genes
were the same as those for the housekeeping gene
GAPDH, the expression level of which was used to nor-
malize the results and assigned an arbitrary value of 1. The
sequences of the human specific primers were 5'-CAGAA-
CATCATCCCTGCCTCT(S) and 5'-GCTTGACAAAGTGG
TCGTTGAG(AS) for GAPDH, 5'-CTTAGAGGTG ACT-
GGCAAAC(S) and 5'-GCCCATCAAATGGGTAGAAG(AS)
for MMP-13, 5'-TGAAGCAGTGAAGAAGGAC(S) and 5'-
CTGCTTTCTCTTGTAGAATC(AS) for IGFBP-5, 5'-GAGAT-
GCCTTCAGCAGAGTG(S) and 5'-ACATGCGCCTTGATGT
CTG(AS) for IL-10, 5'-CTCACATCAAGCTACAACTTC(S)
and 5'-GGTCCTGTTTTGGATCCAAG(AS) for basic fibrob-
last growth factor (bFGF).
Extraction and quantification of miRNAs
miRNA was extracted with the mirVana kit (Ambion, Aus-
tin, TX, USA). This kit is designed especially for the isola-
tion of small RNAs by enriching the population of RNAs
that are 200 bases and smaller. The extracted RNA was
reverse-transcribed with the TaqMan MicroRNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA,
USA); the miRNAs miR-140 and miR-27a were quantified
with TaqMan MicroRNA Assays specific for each mature
miRNA (Applied Biosystems). Normalization of the
miRNA expression data was done with the endogenous
control gene RNU24 (small nucleolar RNU24), the
expression of which has been shown to be high with little
variation across tissue samples; it was assigned an arbi-
trary value of 1. The control gene was processed similarly
to the miRNAs by extraction with the mirVana kit fol-
lowed by the specific TaqMan microRNA assay.
Transfection of pre-miR and anti-miR molecules
OA chondrocytes were transfected with pre-miRNA and
anti-miRNA molecules specifically targeting the human
miR-140 and miR-27a (45 nM final concentration;
Applied Biosystems) in DMEM and the HiPerfect Trans-
fection Reagent (3% final concentration; Qiagen). Fluo-
rescent Cy™3-labeled double-stranded RNA
oligonucleotides (45 nM final concentration) were used
to monitor transfection efficiency. This protocol routinely
results in a chondrocyte transfection efficiency of more
than 90%. Cells, either non-transfected or transfected
with non-targeting (random) pre-miRNA or anti-miRNA,
served as controls and provided similar results.BMC Musculoskeletal Disorders 2009, 10:148 http://www.biomedcentral.com/1471-2474/10/148
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Protein production
The culture media were used for quantification of protein
production. MMP-13 protein levels were quantified with
the Fluorokine MAP Human MMP-13 kit (sensitivity 82
pg/ml; R&D Systems, Minneapolis, MN, USA) using the
LiquiChip Luminex apparatus (Qiagen). IGFBP-5 protein
levels were measured using the DuoSet ELISA Develop-
ment kit (sensitivity 300 pg/ml; R&D Systems).
Statistical analysis
Values are expressed as mean ± SEM. Statistical signifi-
cance was assessed using the Student's t-test; p value ≤
0.05 was considered significant.
Results
Basal and induced IGFBP-5 expression levels
In contrast to MMP-13 levels, which are significantly up-
regulated in human OA cartilage [5,8], very little is known
about the regulation of IGFBP-5 in this tissue. We first
determined if IGFBP-5 was expressed in human chondro-
cytes and compared its level between normal and OA. Fur-
ther, we looked at potential regulators of IGFBP-5
expression in OA chondrocytes.
IGFBP-5 was expressed in normal and OA chondrocytes,
and its level was significantly reduced (p < 0.04) in OA
when compared to normal (Figure 1A). Treatment of OA
chondrocytes with cytokines (IL-1β, TNF-α, IFN-γ, IL-10,
and IL-4) and growth factors (TGF-β, BMP-2, and EGF)
involved in arthritis pathophysiology showed that IGFBP-
5 expression was increased by all the cytokines tested with
statistical significance reached for TNF-α (p < 0.02), IFN-γ
(p < 0.0003), and IL-10 (p < 0.01). TGF-β, but not the
other two growth factors, BMP-2 and EGF, significantly
up-regulated (p < 0.004) its expression level (Figure 1B).
Bioinformatic prediction of miRNAs targeting MMP-13 
andIGFBP-5 mRNAs
To pursue the study of factors regulating MMP-13 and
IGFBP-5 expression, more specifically those acting at the
3'-UTR, we investigated the role of miRNAs. To this end,
the 3'-UTR sequences of MMP-13 and IGFBP-5 were ana-
lyzed by several computational algorithms (computa-
tional programs: http://www.microrna.org, http://
www.targetscan.org, http://pictar.mdc-berlin.de, http://
cbio.mskcc.org and http://lgmb.fmrp.usp.br/mirnapath)
which utilize distinct parameters to predict the probability
of a functional miRNA binding site within the 3'-UTR
sequence of a given mRNA. All five computational pro-
grams predicted potential pairing sites for miR-140 and
miR-27a in MMP-13 and IGFBP-5 3'-UTRs (Figure 2).
Presence and effect of miR-140 and miR-27a in OA 
chondrocytes
Firstly, we investigated if miR-140 and miR-27a are
expressed in human chondrocytes. Data revealed that
both miRNAs are expressed in human OA chondrocytes at
about the same level as the RNU24 control gene, which
was given an arbitrary value of 1. Values of 0.88 and 0.94
fold change were recorded for miR-140 and miR-27a
respectively. Prediction of a hybridization site does not
necessarily confirm its functionality, thus validation is
required. To this end, we used pre-miRNA and anti-
miRNA molecules to determine the effects of miR-140
and miR-27a on the expression of target genes. Pre-miR-
NAs are small chemically modified double-stranded RNA
molecules designed to mimic specific endogenous mature
miRNAs, whereas anti-miRNAs are chemically modified
nucleic acids designed to bind to and inhibit specific
endogenous miRNAs. Therefore, pre-miRNAs enhance
the inhibitory effect of miRNAs while anti-miRNAs antag-
onize the miRNA effect and cause increased expression of
the target genes.
OA chondrocytes were transiently transfected with pre- or
anti-miRNAs specific for miR-140 and miR-27a and incu-
bated for 24, 48 and 72 hours (gene expression) and 72
hours (protein production). IGFBP-5 and MMP-13 pro-
duction were determined. For comparison purposes, we
also determined the expression of two other genes, IL-10
and bFGF, predicted as targets for miR-140 (bFGF) and
miR-27a (IL10); these predictions were also obtained by
the same five computational programs as described
above. The results as illustrated in Figure 3 showed that
treatment with pre-miR-140 or miR27a (Figure 3A) did
not significantly affect MMP-13 expression levels, while
transfection with anti-miR-27a (Figure 3B) increased
MMP-13 expression with time, reaching statistical signifi-
cance (p < 0.05) at 72 hours. Treatment with anti-miR-
140 did not affect MMP-13 expression (Figure 3B).
In contrast to MMP-13, these miRNAs differently affected
the expression level of IGFBP-5 (Figure 4). Treatment with
pre-miR-140 significantly inhibited (p = 0.0002) IGFBP-5
expression at as early as 24 hours (Figure 4A), while treat-
ment with the anti-miR-140 significantly increased (p =
0.05) IGFBP-5 expression at 24 hours and 72 hours (p <
0.01) (Figure 4B). Because the cells were affected as early
as 24 hours post-treatment, these data suggest that IGFBP-
5 is a direct target of miR-140. IGFBP-5 expression, like
that of MMP-13, was gradually affected by the anti-miR-
27a; an increase was seen after 48 hours and significance
(p < 0.01) reached after 72 hours of incubation (Figure
4B). The expression levels of IL-10 and bFGF were not
affected by either pre- or anti-miRNAs (data not shown).
MMP-13 protein production followed the same pattern as
the RNA expression profile. A significant increase was
noted in chondrocytes treated with anti-miR-27a (1.5 ±
0.2 fold increase, p < 0.05, n = 8), but treatment with anti-
miR-140 or with the pre-miRNAs did not significantly
affect MMP-13 production. We also looked at the IGFBP-BMC Musculoskeletal Disorders 2009, 10:148 http://www.biomedcentral.com/1471-2474/10/148
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5 protein levels using the only commercially available
ELISA. However, the IGFBP-5 basal level in four out of
eight specimens was at the limit of detection of the assay.
For the four specimens in which the IGFBP-5 level was
detectable, data showed that treatment with both anti-
miR-27a and anti-miR-140 induced a marked increase in
level and values of 2.0 ± 1.1 and 3.0 ± 1.0 fold increase
respectively were recorded.
All together, these data suggest that miR-140 acts directly
on IGFBP-5 and miR-27a acts indirectly on both genes.
Changes in the protein levels could result from the miR-
NAs promoting mRNA degradation combined with their
interference with protein translation.
Regulation of miR-140 and miR-27a expression levels 
inchondrocytes
To determine whether miR-140 and miR-27a could play a
role in the OA disease process, we compared their expres-
sion levels between normal and OA chondrocytes and
identified possible regulatory factors. Data (Figure 5A)
showed no significant difference in miR-27a expression
IGFBP-5 expression and regulation in human chondrocytes Figure 1
IGFBP-5 expression and regulation in human chondrocytes. (A) Total RNA was extracted from normal (n = 6) and 
OA (n = 6) human chondrocytes and processed for real-time PCR/SybrGreen. (B) Human OA chondrocytes (n = 5) were 
treated with cytokines and growth factors; total RNA was extracted and processed for real-time PCR/SybrGreen. Levels of the 
untreated (CTL) cells were given an arbitrary value of 1.
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between normal and OA chondrocytes although a slight
decrease (23%) was observed in the OA. In contrast, miR-
140 expression was significantly reduced (p < 0.01) in OA
chondrocytes; a 77% reduction was found when com-
pared to the expression in the normal cells.
OA chondrocytes were treated with cytokines and growth
factors to identify those responsible for the differential
expression of the miRNAs. miR-140 expression was signif-
icantly reduced (p < 0.03) by TGF-β (Figure 5B); it was
also reduced by BMP-2, although not quite reaching sta-
tistical significance. None of the other factors tested
affected miR-140 expression. In contrast, the cytokines IL-
10 (p < 0.01) and IFN-γ (p < 0.02) significantly reduced
the miR-27a levels.
Discussion
The objective of this study was to complement the data on
MMP-13 and IGFBP-5 regulation at the gene expression
level by determining if miRNAs could affect the regulation
of these genes and, if so, to identify and validate those
miRNAs. Understanding the regulation of these factors is
Predicted recognition sequences for miR-140 and miR-27a in the 3'-UTR of the MMP-13 and IGFBP-5 mRNAs Figure 2
Predicted recognition sequences for miR-140 and miR-27a in the 3'-UTR of the MMP-13 and IGFBP-5 mRNAs. 
The 3'-UTRs were analyzed by computational programs to predict the presence of functional miR-140 and miR-27a sites. (A) 
Schematic representation of the mRNAs; ORF (open reading frame), ATG (start codon), TAA and TGA (stop codons), bp 
(base pair). The numbering starts at the first base following the stop codon. The arrows indicate the location of the potential 
pairing sites for the miRNAs. (B) Sequences of the potential pairing sites for miR-27a and miR-140. The bars indicate base pair 
homology.
ATG TAA
miR-27a
(89-111)
miR-140
(153-175)
1 1278
3’-UTR ORF
bp
ATG TGA
miR-140
(3837-3845)
1 4630
3’-UTR ORF
bp
MMP-13
IGFBP-5
A
B
|
MMP-13 3’-UTR  5’GGAGAAAGCUUGGUU-CUGUGAAC
miR-27a            3’ CGCCUUGAAUCGGUGACACUU
| || | | | ||
|| || || | ||
miR-140  3’    GAUGGUAUCCCAUUUUGGUGA
IGFBP-5 3’-UTR 5’CUGUCUGUGUUUUUAAAACCACU
| | | || | || | || |
miR-140           3’ GAUGGUAUCCCAUUUUGGUGA
MMP-13 3’-UTR  5’ACUAUGCGUGGCUGGAACCACAUBMC Musculoskeletal Disorders 2009, 10:148 http://www.biomedcentral.com/1471-2474/10/148
Page 7 of 11
(page number not for citation purposes)
of great importance and could provide a new basis for the
rationalization of a therapeutic strategy. Since several
reports on miRNA profiling human cartilage [32], cancer
[23] and general human tissues [21,36] have already been
published, we chose to follow up on MMP-13 and IGFBP-
5 and focus our research on the expression and regulation
of miR-140 and miR-27a, as these miRNAs were identified
with high prediction by the five computational programs
used as possible regulators of both MMP-13 and IGFBP-5
expression.
Many factors contribute to the overall degradation of car-
tilage in OA. MMP-13 is well known to be up-regulated
and to play a major role in the pathophysiological process
of OA [1,4,5]. On the other hand, the exact function of
IGFBP-5 in cartilage is not totally understood, but it is sug-
gested to play a role as facilitator of IGF-1 availability in
the tissue. Indeed, IGFBP-5 has been shown to associate
with extracellular matrix macromolecules where it is pro-
tected from degradation and acts as a local reservoir for
IGF-1 [11]. In this bound state, its affinity for IGF-1 is
decreased when compared to the soluble state [11], indi-
cating that IGFBP-5 would facilitate the delivery of this
growth factor to its specific cell surface receptors. In OA,
decreased levels of IGFBP-5 would diminish the capacity
of the extracellular matrix to act as a reservoir for IGF-1;
the free IGF-1 could then be sequestered by other IGFBPs,
such as IGFBP-3 known to be increased in OA [37], result-
ing in its reduced bio-availability.
Data showed that the IGFBP-5 expression level was signif-
icantly decreased in human OA chondrocytes. This con-
curs with results from a study on another articular cell, the
human subchondral bone osteoblast, in which the IGFBP-
5 was down-regulated in OA [38]. However, it is in con-
trast to earlier studies reporting increased expression/pro-
duction of IGFBP-5 in OA cartilage/chondrocytes [39,40].
Previous data [41], including our own [37], have shown
that the IGFBP-5 protein basal level in human OA
chondrocytes was undetectable or very low and subjected
to the action of proteases. It is possible that variations may
have occurred depending on the culture conditions as
well as the variability of the different measurement meth-
ods used in those studies (immunohistochemistry, West-
ern blot, semi-quantitative PCR). Here, we used more
sensitive methods including quantitative PCR and a spe-
cific ELISA.
As IGFBP-5 is essential for maintaining IGF-1 anabolic
activity, knowing the factor(s) responsible for its
decreased expression level is important. Findings in the
literature indicate that IGFBP-5 protein could be degraded
Effect of pre- and anti-miR-140 and miR-27a on MMP-13 gene expression Figure 3
Effect of pre- and anti-miR-140 and miR-27a on MMP-13 gene expression. OA chondrocytes (n = 8) were trans-
fected with the pre-miR (A) and anti-miR (B) molecules and incubated for 24, 48 and 72 hours. Total RNA was extracted and 
processed for real-time PCR/TaqMan. Levels from untreated chondrocytes (-) were assigned an arbitrary value of 1.
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by proteases and the serine protease Complement 1s, an
enzyme present in the OA joint, was recently identified as
being responsible for the cleavage of IGFBP-5 [41]. How-
ever, there are very few reports on gene expression. The
present study showed that the IGFBP-5 gene expression is
down-regulated by miR-140. This appears to be a direct
effect, as IGFBP-5 is regulated as early as 24 hours post-
treatment by the pre- and anti-miR-140. Although data
showed that miR-140 is a regulatory factor of IGFBP-5,
this does not imply that it is the only factor to down-reg-
ulate IGFBP-5, as miR-140 is also decreased in OA.
Indeed, each gene is regulated by a variety of factors, some
stimulatory and others suppressive. The decreased expres-
sion of IGFBP-5 in OA is the outcome of the interplay
between these factors in which miR-140 plays a role.
Interestingly, MMP-13 and bFGF, which were also pre-
dicted to be miR-140 targets, were not affected by this
miRNA. These latter data indicate that corroboration is
necessary to conclude the specificity of a predicted target
for a given miRNA.
Recent studies reported the role of some miRNAs in MMP
regulation. For example, Stanczyk et al [24] demonstrated
that the over-expression of miR-155 in RA synovial
fibroblasts induced the repression of MMP-3 but not of
MMP-13. However, MMP-3 has not yet been validated as
a direct target of miR-155. On the other hand, Jones et al
[42] recently reported that miR-9 could modulate MMP-
13 expression, and Yamasaki et al [28] found, in OA carti-
lage, an association between the decreased expression of
miR-146a and the increased MMP-13 expression level.
Again, MMP-13 as a direct target of these miRNAs was not
validated. Indirect regulation of MMP activity by miRNAs
has also been recently reported in cancer cells [43]; miR-
21 is over-expressed in glioblastomas and targets tissue
inhibitor metalloprotease-3, a regulator of some MMPs.
Moreover, on chondrocytes, miR-22 was shown to act on
MMP-13 but through an effect on two other factors,
PPARα and BMP-7 [32]. Thus, the control of gene expres-
sion by miRNAs can be both direct and indirect.
In this study, we show that MMP-13, as well as IGFBP-5,
are likely indirect targets of miR-27a. Pre-miR-27a did not
affect expression and anti-miR-27a treatment started to
up-regulate transcription at 48 hours post-treatment, an
increase which became significant after 72 hours. Of note,
another gene predicted to be a target of miR-27a, IL-10,
was not affected by either this pre- or anti-miRNA.
Data on MMP-13 and IGFBP-5 indicate that miR-27a
affects the expression of another factor (or factors), which
in turn acts on these two genes. It is likely that the factor
is a stimulatory regulator of both IGFBP-5 and MMP-13
expression as they are affected only by the anti-miR-27a
and not by the pre-miR-27a. The anti-miRNA would
Effect of pre- and anti-miR-140 and -27a on IGFBP-5 gene expression levels Figure 4
Effect of pre- and anti-miR-140 and -27a on IGFBP-5 gene expression levels. OA chondrocytes (n = 7-8) were trans-
fected with the pre-miR (A) and anti-miR (B) molecules and incubated for 24, 48 and 72 hours. Total RNA was extracted and 
processed for real-time PCR/TaqMan. Levels from untreated chondrocytes (-) were assigned an arbitrary value of 1.
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antagonize the inhibitory effect of miR-27a on the stimu-
latory factor resulting in its increased expression, which,
in turn, would affect IGFBP-5 and MMP-13.
Although the identification of the miR-27a-targeted inter-
mediate factor is currently ongoing, the computational
programs have identified only a few miR-27a target genes
that could have the potential to code for MMP-13 regula-
tory factors, and include PPARγ and Smad2. However, as
the activation of PPARγ inhibits rather than stimulates
MMP-13 expression [44], Smad2 is a more likely candi-
date. Although the IGFBP-5 promoter has been cloned
and sequenced [45,46] it has not been fully characterized.
However, our results show that TGF-β strongly stimulates
IGFBP-5 expression, and Smad2 is implicated in TGF-β
signaling [47] TGF-β has also been reported to up-regulate
MMP-13 expression [8,48] and data further showed that
the TGF-β-induced MMP-13 production in human OA
chondrocytes was triggered by Smad proteins [49]. How-
ever, given the large number of potential miR-27a targets,
the possibility that miR-27a targets two different regula-
tory factors for MMP-13 and IGFBP-5 is also considered.
Even though stimulators of IGFBP-5 were found in this
study and include the cytokines TNF-α, IFN-γ and IL-10,
and the growth factor TGF-β, they do not seem to be suf-
ficient to maintain normal IGFBP-5 levels in OA chondro-
cytes, as the level of IGFBP-5 was significantly reduced in
the diseased cells. This could be explained by the fact that
OA chondrocytes do not produce these cytokines at high
levels [50], in addition to the slightly increased miR-140
expression following TNF-α treatment. However, because
of the differential role of TGF-β in the regulation of
IGFBP-5 and miR-140, the low level of IGFBP-5 in OA
chondrocytes was surprising. TGF-β significantly reduced
miR-140 expression levels at the same time as strongly up-
regulating IGFBP-5. Thus, TGF-β would act in two differ-
ent ways to increase IGFBP-5: directly on its transcription,
Expression and regulation of miR-27a and miR-140 levels in human chondrocytes Figure 5
Expression and regulation of miR-27a and miR-140 levels in human chondrocytes. (A) Total RNA was extracted 
from normal (n = 6) and OA (n = 6) human chondrocytes and processed for real-time PCR/TaqMan. (B) OA chondrocytes (n 
= 5) were treated with cytokines and growth factors and miRNAs were extracted and processed for real-time PCR/TaqMan. 
Levels of the untreated (CTL) cells were given an arbitrary value of 1.
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possibly at the promoter level, and indirectly by decreas-
ing miR-140, a transcription inhibitor.
Reports on miRNA regulation/modulation are scarce. Our
study is the first to show the regulation of the two miR-
NAs, miR-140 and miR-27a, in OA chondrocytes. Data
show that TGF-β, known to be increased in OA cartilage
[51,52], is a candidate for the reduced expression of miR-
140 in these cells. As for miR-27a, among the factors
tested, only IFN-γ and IL-10 decreased its expression.
However, as mentioned above, these two factors are not
found at high levels in OA [50] which could explain that
only a slight reduction in miR-27a was found in OA
chondrocytes.
Conclusion
This study is the first to report on the regulation of miR-
NAs in OA chondrocytes. We show that miR-140 levels
are decreased in OA and that the decrease could be attrib-
uted to the growth factor TGF-β. Data also suggest that
miR-140 could act directly on decreasing IGFBP-5 expres-
sion but that miR-27a indirectly decreases both MMP-13
and IGFBP-5. These findings add another level of com-
plexity to the overall regulation of MMP-13 and IGFBP-5,
two factors involved in the OA pathological process. Data
acquired from the study of these two genes could be the
first step in generating more comprehensive knowledge of
the regulation of other MMPs and IGFBPs involved in OA,
which could open up novel avenues in therapeutic strate-
gies targeting this disease.
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